

MME Antibody (Center) Blocking Peptide
Synthetic peptide
Catalog # BP7329c**Specification**

MME Antibody (Center) Blocking Peptide - Product InformationPrimary Accession [P08473](#)**MME Antibody (Center) Blocking Peptide - Additional Information**

Gene ID 4311

Other Names

Neprilysin, Atriopeptidase, Common acute lymphocytic leukemia antigen, CALLA, Enkephalinase, Neutral endopeptidase 2411, NEP, Neutral endopeptidase, Skin fibroblast elastase, SFE, CD10, MME, EPN

Target/Specificity

The synthetic peptide sequence used to generate the antibody [AP7329c](/products/AP7329c) was selected from the Center region of human MME. A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.

Format

Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed.

Storage

Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.

Precautions

This product is for research use only. Not for use in diagnostic or therapeutic procedures.

MME Antibody (Center) Blocking Peptide - Protein Information

Name MME {ECO:0000303|PubMed:27588448, ECO:0000312|HGNC:HGNC:7154}

Function

Thermolysin-like specificity, but is almost confined on acting on polypeptides of up to 30 amino acids (PubMed: [6349683](http://www.uniprot.org/citations/6349683), PubMed: [6208535](http://www.uniprot.org/citations/6208535), PubMed: [15283675](http://www.uniprot.org/citations/15283675), PubMed: [8168535](http://www.uniprot.org/citations/8168535)). Biologically important in the destruction of opioid peptides such as Met- and Leu- enkephalins by cleavage of a Gly-Phe bond (PubMed: [6349683](http://www.uniprot.org/citations/6349683), PubMed: [17101991](http://www.uniprot.org/citations/17101991)). Catalyzes cleavage of bradykinin, substance P and neurotensin peptides (PubMed: [6349683](http://www.uniprot.org/citations/6349683), PubMed: [17101991](http://www.uniprot.org/citations/17101991)).

[6208535](http://www.uniprot.org/citations/6208535)). Able to cleave angiotensin-1, angiotensin-2 and angiotensin 1-9 (PubMed:[6349683](http://www.uniprot.org/citations/6349683), PubMed:[15283675](http://www.uniprot.org/citations/15283675)). Involved in the degradation of atrial natriuretic factor (ANF) and brain natriuretic factor (BNP(1-32)) (PubMed:[2531377](http://www.uniprot.org/citations/2531377), PubMed:[2972276](http://www.uniprot.org/citations/2972276), PubMed:[16254193](http://www.uniprot.org/citations/16254193)). Displays UV-inducible elastase activity toward skin preelastic and elastic fibers (PubMed:[20876573](http://www.uniprot.org/citations/20876573)).

Cellular Location

Cell membrane; Single-pass type II membrane protein

MME Antibody (Center) Blocking Peptide - Protocols

Provided below are standard protocols that you may find useful for product applications.

- [Blocking Peptides](#)

MME Antibody (Center) Blocking Peptide - Images

MME Antibody (Center) Blocking Peptide - Background

MME is a common acute lymphocytic leukemia antigen that is an important cell surface marker in the diagnosis of human acute lymphocytic leukemia (ALL). This protein is present on leukemic cells of pre-B phenotype, which represent 85% of cases of ALL. This protein is not restricted to leukemic cells, however, and is found on a variety of normal tissues. It is a protein that is particularly abundant in kidney, where it is present on the brush border of proximal tubules and on glomerular epithelium. The protein is a neutral endopeptidase that cleaves peptides at the amino side of hydrophobic residues and inactivates several peptide hormones including glucagon, enkephalins, substance P, neurotensin, oxytocin, and bradykinin.

MME Antibody (Center) Blocking Peptide - References

Dakka,N., Bellaoui,H. *Pediatr Hematol Oncol* 26 (4), 216-231 (2009)Wang,R., Wang,S. J. *Neurochem.* 108 (4), 1072-1082 (2009)Shipp,M.A. *Proc. Natl. Acad. Sci. U.S.A.* 88 (23), 10662-10666 (1991)Shipp,M.A. *Proc. Natl. Acad. Sci. U.S.A.* 86 (1), 297-301 (1989)